BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32666903)

  • 1. Prognostic performance of copeptin among patients with acute decompensated heart failure.
    Ozmen C; Deveci OS; Tepe O; Yesildas C; Ünal İ; Yıldız İ; Eker Akıllı R; Deniz A; Demir M; Kanadaşı M; Usal A
    Acta Cardiol; 2021 Oct; 76(8):842-851. PubMed ID: 32666903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial.
    Jia J; Chang GL; Qin S; Chen J; He WY; Lu K; Li Y; Zhang DY
    Exp Ther Med; 2017 Apr; 13(4):1554-1560. PubMed ID: 28413508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
    Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
    Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Protasov VN; Narusov OY; Skvortsov AA; Protasova DE; Kuznetsova TV; Petrukhina AA; Masenko VP; Tereshchenko SN
    Kardiologiia; 2019 Jan; 59(1S):53-64. PubMed ID: 30706839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.
    Khan SQ; Dhillon OS; O'Brien RJ; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
    Circulation; 2007 Apr; 115(16):2103-10. PubMed ID: 17420344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
    Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
    ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
    Suzuki S; Sugiyama S
    Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study.
    Winther JA; Brynildsen J; Høiseth AD; Strand H; Følling I; Christensen G; Nygård S; Røsjø H; Omland T
    Respir Res; 2017 Nov; 18(1):184. PubMed ID: 29100503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study.
    Wannamethee SG; Welsh P; Whincup PH; Lennon L; Papacosta O; Sattar N
    Eur J Heart Fail; 2014 Jan; 16(1):25-32. PubMed ID: 23901058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication.
    Ordu S; Ozhan H; Alemdar R; Aydin M; Caglar O; Yuksel H; Kandis H
    Tex Heart Inst J; 2012; 39(1):30-5. PubMed ID: 22412224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copeptin in heart failure: Review and meta-analysis.
    Zhong Y; Wang R; Yan L; Lin M; Liu X; You T
    Clin Chim Acta; 2017 Dec; 475():36-43. PubMed ID: 28982590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copeptin and risk stratification in patients with acute dyspnea.
    Potocki M; Breidthardt T; Mueller A; Reichlin T; Socrates T; Arenja N; Reiter M; Morgenthaler NG; Bergmann A; Noveanu M; Buser PT; Mueller C
    Crit Care; 2010; 14(6):R213. PubMed ID: 21106053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
    Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
    ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke.
    Tu WJ; Ma GZ; Ni Y; Hu XS; Luo DZ; Zeng XW; Liu Q; Xu T; Yu L; Wu B
    Neurology; 2017 May; 88(20):1899-1905. PubMed ID: 28424274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of copeptin and cancer antigen 125 in acute heart failure patients with atrial fibrillation and their correlations with short-term cardiovascular events].
    Ding Y; Wang Q; Yang Y; Wang L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Nov; 30(11):1024-1028. PubMed ID: 30541639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
    Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
    Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.
    Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Damman P; Tijssen JG; Pinto YM
    Heart; 2014 Jan; 100(2):115-25. PubMed ID: 24179162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF.
    O'Brien RJ; Squire IB; Demme B; Davies JE; Ng LL
    Eur J Heart Fail; 2003 Aug; 5(4):499-506. PubMed ID: 12921811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    JAMA; 2011 May; 305(20):2088-95. PubMed ID: 21610241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.